Take tab continuously w/o regard to vag bleeding. Stop any hormonal contraception prior to treatment initiation. May aggravate uterine bleeding. Consider discontinuation in the event of anemia. Changes in menstrual bleeding pattern. Slightly enhanced risk of stroke in women w/ HTN. Discontinue treatment in case of long-term immobilization (at least 4 wk in advance in case of elective surgery) & do not resume treatment until 2 wk after complete remobilization. Consider increased risk of thromboembolism in the puerperium. Discontinue treatment in case of symptoms of arterial or venous thrombotic event or suspicion thereof. Reports, in rare cases, of benign liver tumours, & even more rarely, malignant liver tumours. Changes in bone mineral density. W/draw treatment if a sustained clinically significant HTN develops during use. Discontinue use upon recurrence of cholestatic jaundice &/or pruritus which occurred 1st during pregnancy or previous use of sex steroids. May have slight effect on peripheral insulin resistance & glucose tolerance. Chloasma may occasionally occur, especially in women w/ history of chloasma gravidarum. Persistent ovarian follicles may occur during use. May influence the results of certain lab tests, including biochemical parameters of liver, thyroid, adrenal & renal function, plasma levels of (carrier) proteins (eg, corticosteroid binding globulin & lipid/lipoprotein fractions), parameters of carbohydrate metabolism, & parameters of coagulation & fibrinolysis. Patients w/ increased risk of osteoporosis; history of depression; history of extrauterine pregnancy or impairment of tube function; rare hereditary problems of galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption. Do not administer to pregnant women. Not recommended during lactation. Inhibited ovulation during treatment. Menstrual cycle returns to normal w/in 2 mth after treatment cessation. Not indicated in childn prior to menarche. No relevant indication in the elderly.
Sign Out
